Giulio F. Draetta, M.D., Ph.D.

Peer-Reviewed Articles

1. Takeda M, Theardy MS, Sorokin A, Coker O, Kanikarla P, Chen S, Yang Z, Nguyen P, Wei Y, Yao J, Wang X, Yan L, Jin Y, Cai Y, Paku M, Chen Z, Li KZ, Citron F, Tomihara H, Gao S, Deem AK, Zhao J, Wang H, Hanash S, DePinho RA, Maitra A, Draetta GF, Ying H, Kopetz S, Yao W. Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. bioRxiv None(None):None, 2024. PMID: None.
2. Ho IL, Li CY, Wang F, Zhao L, Liu J, Yen EY, Dyke CA, Shah R, Liu Z, Çetin AO, Chu Y, Citron F, Attanasio S, Corti D, Darbaniyan F, Del Poggetto E, Loponte S, Liu J, Soeung M, Chen Z, Jiang S, Jiang H, Inoue A, Gao S, Deem A, Feng N, Ying H, Kim M, Giuliani V, Genovese G, Zhang J, Futreal A, Maitra A, Heffernan T, Wang L, Do KA, Gargiulo G, Draetta G, Carugo A, Lin R, Viale A. Clonal dominance defines metastatic dissemination in pancreatic cancer. Sci Adv 10(11):eadd9342, 2024. e-Pub 2024. PMID: 38478609.
3. Perelli L, Zhang L, Mangiameli S, Russell AJC, Giannese F, Peng F, Carbone F, Le C, Khan H, Citron F, Soeung M, Lam TNA, Lundgren S, Zhu C, Catania D, Feng N, Gurreri E, Sgambato A, Tortora G, Draetta GF, Tonon G, Futreal A, Giuliani V, Carugo A, Viale A, Heffernan TP, Wang L, Cittaro D, Chen F, Genovese G. Evolutionary fingerprints of EMT in pancreatic cancers. bioRxiv, 2023. e-Pub 2023. PMID: 37786705.
4. Noh, S, Bertini, CD, Mira-Avendano, I, Kaous, M, Patel, B, Faiz, S, Shannon, VR, Balachandran, D, Bashoura, L, Adachi, R, Evans, S, Dickey, BF, Wu, CC, Shroff, G, Manzano, JM, Granwehr, BP, Holloway, S, Dickson, KB, Mohammed, AD, Muthu, M, Song, H, Aroe, A, Aloia, TA, Lee Andrews, II, Badami, KK, Beird, H, Brock, K, Cata, JP, Dabaja, BS, Draetta, G, French, KE, Godoy, M, Hutcheson, KA, Jaffray, D, John, TM, Lee, JJ, Litton, J, McEnery, KW, Musunuru, TN, Nates, JL, Palaskas, NL, Ravi, V, Scheet, PA, Shete, S, Subbiah, IM, Tawbi, H, Woodman, SE, Chung, C, Khawaja, F, Sheshadri, A. Interstitial lung abnormalities after hospitalization for COVID-19 in patients with cancer. Cancer medicine 12(17):17753-17765, 2023. PMID: 37592894.
5. Perelli L, Carbone F, Zhang L, Huang JK, Le C, Khan H, Citron F, Del Poggetto E, Gutschner T, Tomihara H, Soeung M, Minelli R, Srinivasan S, Peoples M, Lam TNA, Lundgren S, Xia R, Zhu C, Mohamed AMT, Zhang J, Sircar K, Sgambato A, Gao J, Jonasch E, Draetta GF, Futreal A, Bakouny Z, Van Allen EM, Choueiri T, Signoretti S, Msaouel P, Litchfield K, Turajlic S, Wang L, Chen YB, Di Natale RG, Hakimi AA, Giuliani V, Heffernan TP, Viale A, Bristow CA, Tannir NM, Carugo A, Genovese G. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nat Cancer. e-Pub 2023. PMID: 37365326.
6. Soeung M, Perelli L, Chen Z, Dondossola E, Ho IL, Carbone F, Zhang L, Khan H, Le CN, Zhu C, Peoples MD, Feng N, Jiang S, Zacharias NM, Minelli R, Shapiro DD, Deem AK, Gao S, Cheng EH, Lucchetti D, Walker CL, Carugo A, Giuliani V, Heffernan TP, Viale A, Tannir NM, Draetta GF, Msaouel P, Genovese G. SMARCB1 regulates the hypoxic stress response in sickle cell trait. Proc Natl Acad Sci U S A 120(21):e2209639120, 2023. e-Pub 2023. PMID: 37186844.
7. Chen Z, Ho IL, Soeung M, Yen EY, Liu J, Yan L, Rose JL, Srinivasan S, Jiang S, Edward Chang Q, Feng N, Gay JP, Wang Q, Wang J, Lorenzi PL, Veillon LJ, Wei B, Weinstein JN, Deem AK, Gao S, Genovese G, Viale A, Yao W, Lyssiotis CA, Marszalek JR, Draetta GF, Ying H. Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis. Nat Commun 14(1):2194, 2023. e-Pub 2023. PMID: 37069167.
8. Reddy, DS, Cuenca, JA, Botdorf, JS, Muthu, M, Hanmandlu, A, Wegner, RC, Crommett, JW, Gutierrez, C, Rathi, N, Sajith, B, Knafl, M, Abbas, HA, Woodman, SE, Nates, JL, Aaroe, AE, Aloia, TA, Andrews, L, Badami, KK, Baganz, JA, Bajwa, P, Baker, LR, Barbosa, GR, Beird, H, Bourgeois, M, Brock, K, Burton, EM, Cata, JP, Chung, C, Cutherell, M, Dabaja, BS, Draetta, G, French, KE, Futreal, A, Gibbons, C, Godoy, M, Gunther, J, Hutcheson, KA, Jaffray, D, John, TM, Lee, JJ, Litton, J, McEnery, KW, Palaskas, NL, Ravi, V, Scheet, PA, Schmidt, S, Subbiah, IM, Tawbi, H, Wu, J, Yao, JC. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19. Mayo Clinic Proceedings 98(3):451-457, 2023. PMID: 36868753.
9. Zhang ZY, Ding Y, Ezhilarasan R, Lhakhang T, Wang Q, Yang J, Modrek AS, Zhang H, Tsirigos A, Futreal A, Draetta GF, Verhaak RGW, Sulman EP. Lineage-coupled clonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAFV600E inhibition resistance in melanoma. Cell Discov 8(1):102, 2022. e-Pub 2022. PMID: 36202798.
10. Zamler DB, Shingu T, Kahn LM, Huntoon K, Kassab C, Ott M, Tomczak K, Liu J, Li Y, Lai I, Zorilla-Veloz R, Yee C, Rai K, Kim BY, Watowich SS, Heimberger AB, Draetta GF, Hu J. Immune landscape of a genetically engineered murine model of glioma compared with human glioma. JCI Insight 7(12), 2022. e-Pub 2022. PMID: 35653194.
11. Ghilardi C, Moreira-Barbosa C, Brunelli L, Ostano P, Panini N, Lupi M, Anastasia A, Fiordaliso F, Salio M, Formenti L, Russo M, Arrigoni E, Chiaradonna F, Chiorino G, Draetta G, Marszalek JR, Vellano CP, Pastorelli R, Bani M, Decio A, Giavazzi R. PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer. Cancer Res 82(7):1423-1434, 2022. PMID: 35131872.
12. Donati G, Ravà M, Filipuzzi M, Nicoli P, Cassina L, Verrecchia A, Doni M, Rodighiero S, Parodi F, Boletta A, Vellano CP, Marszalek JR, Draetta GF, Amati B. Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma. Mol Oncol 16(5):1132-1152, 2022. e-Pub 2021. PMID: 34632715.
13. Draetta GF, Lazarevic D, Provero P, Cittaro D. The frequency of somatic mutations in cancer predicts the phenotypic relevance of germline mutations. Front Genet 13:1045301, 2022. e-Pub 2023. PMID: 36699457.
14. Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, Saridogan T, Shariati M, Class CA, Bristow CA, Vellano CP, Zheng X, Gonzalez-Angulo AM, Su X, Tapia C, Chen K, Akcakanat A, Lim B, Tripathy D, Yap TA, Francesco MED, Draetta GF, Jones P, Heffernan TP, Marszalek JR, Meric-Bernstam F. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Res 81(21):5572-5581, 2021. e-Pub 2021. PMID: 34518211.
15. Puca F, Yu F, Bartolacci C, Pettazzoni P, Carugo A, Huang-Hobbs E, Liu J, Zanca C, Carbone F, Del Poggetto E, Gumin J, Dasgupta P, Seth S, Srinivasan S, Lang FF, Sulman EP, Lorenzi PL, Tan L, Shan M, Tolstyka ZP, Kachman M, Zhang L, Gao S, Deem AK, Genovese G, Scaglioni PP, Lyssiotis CA, Viale A, Draetta GF. Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. Cancer Discov 11(11):2904-2923, 2021. e-Pub 2021. PMID: 34039636.
16. Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34885132.
17. Czako B, Sun Y, McAfoos T, Cross JB, Leonard PG, Burke JP, Carroll CL, Feng N, Harris AL, Jiang Y, Kang Z, Kovacs JJ, Mandal P, Meyers BA, Mseeh F, Parker CA, Yu SS, Williams CC, Wu Q, Di Francesco ME, Draetta GF, Heffernan T, Marszalek JR, Kohl NE, Jones P. Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor. J Med Chem 64(20):15141-15169, 2021. e-Pub 2021. PMID: 34643390.
18. Del Poggetto E, Ho IL, Balestrieri C, Yen EY, Zhang S, Citron F, Shah R, Corti D, Diaferia GR, Li CY, Loponte S, Carbone F, Hayakawa Y, Valenti G, Jiang S, Sapio L, Jiang H, Dey P, Gao S, Deem AK, Rose-John S, Yao W, Ying H, Rhim AD, Genovese G, Heffernan TP, Maitra A, Wang TC, Wang L, Draetta GF, Carugo A, Natoli G, Viale A. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science 373(6561):eabj0486, 2021. e-Pub 2021. PMID: 34529467.
19. Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology 161(1):196-210, 2021. e-Pub 2021. PMID: 33745946.
20. Citron F, Segatto I, Musco L, Pellarin I, Rampioni Vinciguerra GL, Franchin G, Fanetti G, Miccichè F, Giacomarra V, Lupato V, Favero A, Concina I, Srinivasan S, Avanzo M, Castiglioni I, Barzan L, Sulfaro S, Petrone G, Viale A, Draetta GF, Vecchione A, Belletti B, Baldassarre G. miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC. EMBO Mol Med 13(7):e12872, 2021. e-Pub 2021. PMID: 34062049.
21. Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani K. Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest 131(14), 2021. PMID: 34138753.
22. Invrea F, Punzi S, Petti C, Minelli R, Peoples MD, Bristow CA, Vurchio V, Corrado A, Bragoni A, Marchiò C, Bertotti A, Trusolino L, Bardelli A, Isella C, Carugo A, Draetta GF, Medico E. Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways. Cancers (Basel) 13(15), 2021. e-Pub 2021. PMID: 34359705.
23. Giuliani V, Miller MA, Liu CY, Hartono SR, Class CA, Bristow CA, Suzuki E, Sanz LA, Gao G, Gay JP, Feng N, Rose JL, Tomihara H, Daniele JR, Peoples MD, Bardenhagen JP, Geck Do MK, Chang QE, Vangamudi B, Vellano C, Ying H, Deem AK, Do KA, Genovese G, Marszalek JR, Kovacs JJ, Kim M, Fleming JB, Guccione E, Viale A, Maitra A, Emilia Di Francesco M, Yap TA, Jones P, Draetta G, Carugo A, Chedin F, Heffernan TP. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nat Commun 12(1):4626, 2021. e-Pub 2021. PMID: 34330913.
24. Tomihara H, Carbone F, Perelli L, Huang JK, Soeung M, Rose JL, Robinson FS, Lissanu Deribe Y, Feng N, Takeda M, Inoue A, Poggetto ED, Deem AK, Maitra A, Msaouel P, Tannir NM, Draetta GF, Viale A, Heffernan TP, Bristow CA, Carugo A, Genovese G. Loss of ARID1A promotes epithelial-mesenchymal transition and sensitizes pancreatic tumors to proteotoxic stress. Cancer Res 81(2):332-343, 2021. e-Pub 2020. PMID: 33158812.
25. Soth MJ, Le K, Di Francesco ME, Hamilton MM, Liu G, Burke JP, Carroll CL, Kovacs JJ, Bardenhagen JP, Bristow CA, Cardozo M, Czako B, de Stanchina E, Feng N, Garvey JR, Gay JP, Do MKG, Greer J, Han M, Harris A, Herrera Z, Huang S, Giuliani V, Jiang Y, Johnson SB, Johnson TA, Kang Z, Leonard PG, Liu Z, McAfoos T, Miller M, Morlacchi P, Mullinax RA, Palmer WS, Pang J, Rogers N, Rudin CM, Shepard HE, Spencer ND, Theroff J, Wu Q, Xu A, Yau JA, Draetta G, Toniatti C, Heffernan TP, Jones P. Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem 63(21):12957-12977, 2020. e-Pub 2020. PMID: 33118821.
26. Sun Y, Meyers BA, Czako B, Leonard P, Mseeh F, Harris AL, Wu Q, Johnson S, Parker CA, Cross JB, Di Francesco ME, Bivona BJ, Bristow CA, Burke JP, Carrillo CC, Carroll CL, Chang Q, Feng N, Gao G, Gera S, Giuliani V, Huang JK, Jiang Y, Kang Z, Kovacs JJ, Liu CY, Lopez AM, Ma X, Mandal PK, McAfoos T, Miller MA, Mullinax RA, Peoples M, Ramamoorthy V, Seth S, Spencer ND, Suzuki E, Williams CC, Yu SS, Zuniga AM, Draetta GF, Marszalek JR, Heffernan TP, Kohl NE, Jones P. Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinib. Cancer Res 80(21):4840-4853, 2020. e-Pub 2020. PMID: 32928921.
27. Czako B, Marszalek JR, Burke JP, Mandal P, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E, Kovacs JJ, Feng N, Gera S, Harris AL, Liu Z, Mullinax RA, Pang J, Parker CA, Spencer ND, Yu SS, Wu Q, Tremblay MR, Mikule K, Wilcoxen K, Heffernan TP, Draetta GF, Jones P. Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R. J Med Chem 63(17):9888-9911, 2020. e-Pub 2020. PMID: 32787110.
28. Manzo T, Prentice BM, Anderson KG, Raman A, Schalck A, Codreanu GS, Nava Lauson CB, Tiberti S, Raimondi A, Jones MA, Reyzer M, Bates BM, Spraggins JM, Patterson NH, McLean JA, Rai K, Tacchetti C, Tucci S, Wargo JA, Rodighiero S, Clise-Dwyer K, Sherrod SD, Kim M, Navin NE, Caprioli RM, Greenberg PD, Draetta G, Nezi L. Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. J Exp Med 217(8), 2020. PMID: 32491160.
29. Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, Chang Q, Chu GC, Al-Khalil R, Jiang S, Xia H, Fletcher-Sananikone E, Lim C, Horwitz GI, Viale A, Pettazzoni P, Sanchez N, Wang H, Protopopov A, Zhang J, Heffernan T, Johnson RL, Chin L, Wang YA, Draetta G, DePinho RA. Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. Cell 179(5):1239, 2019. PMID: 31730860.
30. Tu B, Yao J, Ferri-Borgogno S, Zhao J, Chen S, Wang Q, Yan L, Zhou X, Zhu C, Bang S, Chang Q, Bristow CA, Kang Y, Zheng H, Wang H, Fleming JB, Kim M, Heffernan TP, Draetta GF, Pan D, Maitra A, Yao W, Gupta S, Ying H. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. JCI Insight 4(21), 2019. e-Pub 2019. PMID: 31557131.
31. Mottini C, Tomihara H, Carrella D, Lamolinara A, Iezzi M, Huang JK, Amoreo CA, Buglioni S, Manni I, Robinson FS, Minelli R, Kang Y, Fleming JB, Kim MP, Bristow CA, Trisciuoglio D, Iuliano A, Del Bufalo D, Di Bernardo D, Melisi D, Draetta GF, Ciliberto G, Carugo A, Cardone L. Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. Cancer Res 79(21):5612-5625, 2019. e-Pub 2019. PMID: 31492820.
32. Liu J, Srinivasan S, Li CY, Ho IL, Rose J, Shaheen M, Wang G, Yao W, Deem A, Bristow C, Hart T, Draetta G. Pooled library screening with multiplexed Cpf1 library. Nat Commun 10(1):3144, 2019. e-Pub 2019. PMID: 31316073.
33. Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical Questions in Ovarian Cancer Research and Treatment: Report of an American Association for Cancer Research Special Conference. Cancer 125(12):1963-1972, 2019. e-Pub 2019. PMID: 30835824.
34. Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, Haun R, Lan R, Mackintosh SG, Mao X, Song X, Zhang J, Pham LV, Lorenzi PL, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, Wang L, Wang M. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med 11(491), 2019. PMID: 31068440.
35. Yao W, Rose JL, Wang W, Seth S, Jiang H, Taguchi A, Liu J, Yan L, Kapoor A, Hou P, Chen Z, Wang Q, Nezi L, Xu Z, Yao J, Hu B, Pettazzoni PF, Ho IL, Feng N, Ramamoorthy V, Jiang S, Deng P, Ma GJ, Den P, Tan Z, Zhang SX, Wang H, Wang YA, Deem AK, Fleming JB, Carugo A, Heffernan TP, Maitra A, Viale A, Ying H, Hanash S, DePinho RA, Draetta GF. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature 568(7752):410-414, 2019. e-Pub 2019. PMID: 30918400.
36. Seth S, Li CY, Ho IL, Corti D, Loponte S, Sapio L, Del Poggetto E, Yen EY, Robinson FS, Peoples M, Karpinets T, Deem AK, Kumar T, Song X, Jiang S, Kang Y, Fleming J, Kim M, Zhang J, Maitra A, Heffernan TP, Giuliani V, Genovese G, Futreal A, Draetta GF, Carugo A, Viale A. Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. Cell Rep 26(6):1518-1532.e9, 2019. PMID: 30726735.
37. Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell 35(2):204-220.e9, 2019. PMID: 30753823.
38. Sun Y, Bandi M, Lofton T, Smith M, Bristow CA, Carugo A, Rogers N, Leonard P, Chang Q, Mullinax R, Han J, Shi X, Seth S, Meyers BA, Miller M, Miao L, Ma X, Feng N, Giuliani V, Geck Do M, Czako B, Palmer WS, Mseeh F, Asara JM, Jiang Y, Morlacchi P, Zhao S, Peoples M, Tieu TN, Warmoes MO, Lorenzi PL, Muller FL, DePinho RA, Draetta GF, Toniatti C, Jones P, Heffernan TP, Marszalek JR. Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation. Cell Rep 26(2):469-482.e5, 2019. PMID: 30625329.
39. Echeverria GV, Powell E, Seth S, Ge Z, Carugo A, Bristow C, Peoples M, Robinson F, Qiu H, Shao J, Jeter-Jones SL, Zhang X, Ramamoorthy V, Cai S, Wu W, Draetta G, Moulder SL, Symmans WF, Chang JT, Heffernan TP, Piwnica-Worms H. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nat Commun 9(1):5079, 2018. e-Pub 2018. PMID: 30498242.
40. Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med 24(7):1036-1046, 2018. e-Pub 2018. PMID: 29892070.
41. Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, Chintala S, Orillion A, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF Seshadri M, Hancock B, Radovich M, Kota J, Buck M, Keilhack H, McCarthy BP, Persohn SA, Territo PR, Zang Y, Irudayaraj J, Tao WA, Hollenhorst P, Pili R. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer Res 77(23):6651-6666, 2017. e-Pub 2017. PMID: 28978636.
42. Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell 32(1):88-100.e6, 2017. e-Pub 2017. PMID: 28669490.
43. Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, Chang Q, Lazar AJ, Sood AK, Drapkin R, DePinho R, Draetta G, Chin L. PRKCI promotes immune suppression in ovarian cancer. Genes Dev 31(11):1109-1121, 2017. e-Pub 2017. PMID: 28698296.
44. Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature 542(7641):362-366, 2017. e-Pub 2017. PMID: 28178232.
45. Dey P, Baddour J, Muller F, Wu CC, Wang H, Liao WT, Lan Z, Chen A, Gutschner T, Kang Y, Fleming J, Satani N, Zhao D, Achreja A, Yang L, Lee J, Chang E, Genovese G, Viale A, Ying H, Draetta G, Maitra A, Wang YA, Nagrath D, DePinho RA. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature 542(7639):119-123, 2017. e-Pub 2017. PMID: 28099419.
46. Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, Akdemir KC, Bristow CA, Robinson FS, Tepper J, Sanchez N, Gupta S, Estecio MR, Giuliani V, Dellino GI, Riva L, Yao W, Di Francesco ME, Green T, D'Alesio C, Corti D, Kang Y, Jones P, Wang H, Fleming JB, Maitra A, Pelicci PG, Chin L, DePinho RA, Lanfrancone L, Heffernan TP, Draetta GF. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep 16(1):133-47, 2016. e-Pub 2016. PMID: 27320920.
47. Bossi D, Cicalese A, Dellino GI, Luzi L, Riva L, D'Alesio C, Diaferia GR, Carugo A, Cavallaro E, Piccioni R, Barberis M, Mazzarol G, Testori A, Punzi S, Pallavicini I, Tosti G, Giacó L, Melloni G, Heffernan TP, Natoli G, Draetta GF, Minucci S, Pelicci P, Lanfrancone L. In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. Cancer Discov 6(6):650-63, 2016. e-Pub 2016. PMID: 27179036.
48. Petrocchi A, Leo E, Reyna NJ, Hamilton MM, Shi X, Parker CA, Mseeh F, Bardenhagen JP, Leonard P, Cross JB, Huang S, Jiang Y, Cardozo M, Draetta G, Marszalek JR, Toniatti C, Jones P, Lewis RT. Identification of potent and selective MTH1 inhibitors. Bioorg Med Chem Lett 26(6):1503-7, 2016. e-Pub 2016. PMID: 26898335.
49. Palmer WS, Poncet-Montange G, Liu G, Petrocchi A, Reyna N, Subramanian G, Theroff J, Yau A, Kost-Alimova M, Bardenhagen JP, Leo E, Shepard HE, Tieu TN, Shi X, Zhan Y, Zhao S, Barton MC, Draetta G, Toniatti C, Jones P, Geck Do M, Andersen JN. Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. J Med Chem 59(4):1440-54, 2016. e-Pub 2015. PMID: 26061247.
50. Gutschner T, Haemmerle M, Genovese G, Draetta GF, Chin L. Post-translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair. Cell Rep 14(6):1555-66, 2016. e-Pub 2016. PMID: 26854237.
51. Viale A, Draetta GF. Metabolic Features of Cancer Treatment Resistance. Recent Results Cancer Res 207:135-56, 2016. PMID: 27557537.
52. Viale A, Draetta GF. Sugar? No Thank You, Just a Deep Breath of Oxygen for Cancer Stem Cells. Cell Metab 22(4):543-5, 2015. PMID: 26445511.
53. Vangamudi B, Paul TA, Shah PK, Kost-Alimova M, Nottebaum L, Shi X, Zhan Y, Leo E, Mahadeshwar HS, Protopopov A, Futreal A, Tieu TN, Peoples M, Heffernan TP, Marszalek JR, Toniatti C, Petrocchi A, Verhelle D, Owen DR, Draetta G, Jones P, Palmer WS, Sharma S, Andersen JN. The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF mutant cancers: Insights from cDNA rescue and PFI-3 inhibitor studies. Cancer Res 75(18):3865-78, 2015. e-Pub 2015. PMID: 26139243.
54. Chiaradonna F, Barozzi I, Miccolo C, Bucci G, Palorini R, Fornasari L, Botrugno OA, Pruneri G, Masullo M, Passafaro A, Galimberti VE, Fantin VR, Richon VM, Pece S, Viale G, Di Fiore PP, Draetta G, Pelicci PG, Minucci S, Chiocca S. Redox mediated suberoylanilide hydroxamic acid (SAHA) sensitivity in breast cancer. Antioxid Redox Signal 23(1):15-29, 2015. e-Pub 2015. PMID: 25897982.
55. Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, Kapoor A, Yao W, Francesco ME, Petrocchi A, Deem AK, Scott K, Colla S, Mills GB, Fleming JB, Heffernan TP, Jones P, Toniatti C, DePinho RA, Draetta GF. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res 75(6):1091-101, 2015. e-Pub 2015. PMID: 25736685.
56. Zhan Y, Kost-Alimova M, Shi X, Leo E, Bardenhagen JP, Shepard HE, Appikonda S, Vangamudi B, Zhao S, Tieu TN, Jiang S, Heffernan TP, Marszalek JR, Toniatti C, Draetta G, Tyler J, Barton M, Jones P, Palmer WS, Geck Do MK, Andersen JN. Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery. Epigenetics Chromatin 8:37, 2015. e-Pub 2015. PMID: 26396593.
57. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Yao W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, Fleming JB, Cantley LC, DePinho RA, Draetta GF. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514(7524):628-32, 2014. e-Pub 2014. PMID: 25119024.
58. Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, Chang Q, Chu GC, Al-Khalil R, Jiang S, Xia H, Fletcher-Sananikone E, Lim C, Horwitz GI, Viale A, Pettazzoni P, Sanchez N, Wang H, Protopopov A, Zhang J, Heffernan T, Johnson RL, Chin L, Wang YA, Draetta G, DePinho RA. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158(1):185-197, 2014. e-Pub 2014. PMID: 24954535.
59. Toniatti C, Jones P, Graham H, Pagliara B, Draetta G. Oncology Drug Discovery: Planning a Turnaround. Cancer Discov 4(4):397-404, 2014. PMID: 24706659.
60. Berman DM, Bosenberg MW, Orwant RL, Thurberg BL, Draetta GF, Fletcher CD, Loda M. Investigative pathology: leading the post-genomic revolution. Lab Invest 92(1):4-8, 2012. e-Pub 2011. PMID: 21986811.
61. Draetta GF, Depinho RA. Cancer drug discovery faces the FACT. Sci Transl Med 3(95):95ps34, 2011. PMID: 21832237.
62. Ellwood-Yen K, Keilhack H, Kunii K, Dolinski B, Connor Y, Hu K, Nagashima K, O'Hare E, Erkul Y, Di Bacco A, Gargano D, Shomer NH, Angagaw M, Leccese E, Andrade P, Hurd M, Shin MK, Vogt TF, Northrup A, Bobkova EV, Kasibhatla S, Bronson RT, Scott ML, Draetta G, Richon V, Kohl N, Blume-Jensen P, Andersen JN, Kraus M. PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models. Cancer Res 71(8):3052-65, 2011. PMID: 21493594.
63. Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon AH, Pan BS, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 177(1):415-23, 2010. e-Pub 2010. PMID: 20489150.
64. Efferson CL, Winkelmann CT, Ware C, Sullivan T, Giampaoli S, Tammam J, Patel S, Mesiti G, Reilly JF, Gibson RE, Buser C, Yeatman T, Coppola D, Winter C, Clark EA, Draetta GF, Strack PR, Majumder PK. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res 70(6):2476-84, 2010. e-Pub 2010. PMID: 20197467.
65. Tammam J, Ware C, Efferson C, O'Neil J, Rao S, Qu X, Gorenstein J, Angagaw M, Kim H, Kenific C, Kunii K, Leach KJ, Nikov G, Zhao J, Dai X, Hardwick J, Scott M, Winter C, Bristow L, Elbi C, Reilly JF, Look T, Draetta G, Van der Ploeg L, Kohl NE, Strack PR, Majumder PK. Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol 158(5):1183-95, 2009. e-Pub 2009. PMID: 19775282.
66. Rao SS, O'Neil J, Liberator CD, Hardwick JS, Dai X, Zhang T, Tyminski E, Yuan J, Kohl NE, Richon VM, Van der Ploeg LH, Carroll PM, Draetta GF, Look AT, Strack PR, Winter CG. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res 69(7):3060-8, 2009. e-Pub 2009. PMID: 19318552.
67. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters R, Draetta G, Sears R, Clurman BE, Look AT. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 204(8):1813-24, 2007. e-Pub 2007. PMID: 17646409.
68. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27(13):4784-95, 2007. e-Pub 2007. PMID: 17470557.
69. Busino L, Bassermann F, Maiolica A, Lee C, Nolan PM, Godinho SI, Draetta GF, Pagano M. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science 316(5826):900-4, 2007. e-Pub 2007. PMID: 17463251.
70. Lewis HD, Leveridge M, Strack PR, Haldon CD, O'neil J, Kim H, Madin A, Hannam JC, Look AT, Kohl N, Draetta G, Harrison T, Kerby JA, Shearman MS, Beher D. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol 14(2):209-19, 2007. PMID: 17317574.
71. Capra M, Nuciforo PG, Confalonieri S, Quarto M, Bianchi M, Nebuloni M, Boldorini R, Pallotti F, Viale G, Gishizky ML, Draetta GF, Di Fiore PP. Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res 66(16):8147-54, 2006. PMID: 16912193.
72. Squatrito M, Mancino M, Sala L, Draetta GF. Ebp1 is a dsRNA-binding protein associated with ribosomes that modulates eIF2alpha phosphorylation. Biochem Biophys Res Commun 344(3):859-68, 2006. e-Pub 2006. PMID: 16631606.
73. Ray D, Terao Y, Nimbalkar D, Chu LH, Donzelli M, Tsutsui T, Zou X, Ghosh AK, Varga J, Draetta GF, Kiyokawa H. Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol Cell Biol 25(8):3338-47, 2005. PMID: 15798217.
74. Boggio R, Colombo R, Hay RT, Draetta GF, Chiocca S. A mechanism for inhibiting the SUMO pathway. Mol Cell 16(4):549-61, 2004. PMID: 15546615.
75. Masciadri B, Areces LB, Carpinelli P, Foiani M, Draetta G, Fiore F. Characterization of the BUD31 gene of Saccharomyces cerevisiae. Biochem Biophys Res Commun 320(4):1342-50, 2004. PMID: 15303280.
76. Squatrito M, Mancino M, Donzelli M, Areces LB, Draetta GF. EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes. Oncogene 23(25):4454-65, 2004. PMID: 15064750.
77. Donzelli M, Busino L, Chiesa M, Ganoth D, Hershko A, Draetta GF. Hierarchical order of phosphorylation events commits Cdc25A to betaTrCP-dependent degradation. Cell Cycle 3(4):469-71, 2004. e-Pub 2004. PMID: 14752276.
78. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, Hershko A, Pagano M, Draetta GF. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426(6962):87-91, 2003. PMID: 14603323.
79. Colombo R, Draetta GF, Chiocca S. Modulation of p120E4F transcriptional activity by the Gam1 adenoviral early protein. Oncogene 22(17):2541-7, 2003. PMID: 12730668.
80. Colombo R, Boggio R, Seiser C, Draetta GF, Chiocca S. The adenovirus protein Gam1 interferes with sumoylation of histone deacetylase 1. EMBO Rep 3(11):1062-8, 2002. e-Pub 2002. PMID: 12393750.
81. Donzelli M, Squatrito M, Ganoth D, Hershko A, Pagano M, Draetta GF. Dual mode of degradation of Cdc25 A phosphatase. EMBO J 21(18):4875-84, 2002. PMID: 12234927.
82. Chiocca S, Kurtev V, Colombo R, Boggio R, Sciurpi MT, Brosch G, Seiser C, Draetta GF, Cotten M. Histone deacetylase 1 inactivation by an adenovirus early gene product. Curr Biol 12(7):594-8, 2002. PMID: 11937030.
83. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, Meloche S. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 20(23):6672-82, 2001. PMID: 11726503.
84. Soncini C, Berdo I, Draetta G. Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease. Oncogene 20(29):3869-79, 2001. PMID: 11439350.
85. Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF. Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep 1(1):71-9, 2000. PMID: 11256629.
86. Piva R, Cancelli I, Cavalla P, Bortolotto S, Dominguez J, |Draetta GF, Schiffer D. Proteasome-dependent degradation of p27/kip1 in gliomas. J Neuropathol Exp Neurol 58(7):691-6, 1999. PMID: 10411338.
87. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 13(9):1181-9, 1999. PMID: 10323868.
88. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 153(3):681-7, 1998. PMID: 9736017.
89. Naviglio S, Mattecucci C, Matoskova B, Nagase T, Nomura N, Di Fiore PP, Draetta GF. UBPY: a growth-regulated human ubiquitin isopeptidase. EMBO J 17(12):3241-50, 1998. PMID: 9628861.
90. Draetta GF. 11th European Cell Cycle Conference: April 23-26, 1997, Gardone Riviera (Italy) and Symposium on Cell Cycle Regulation (17th International Congress of Biochemistry and Molecular Biology): August 24-29, 1997, San Francisco, CA. Biochim Biophys Acta 1377(1):R11-20, 1998. PMID: 9540812.
91. Lamphere L, Fiore F, Xu X, Brizuela L, Keezer S, Sardet C, Draetta GF, Gyuris J. Interaction between Cdc37 and Cdk4 in human cells. Oncogene 14(16):1999-2004, 1997. PMID: 9150368.
92. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57(7):1259-63, 1997. PMID: 9102210.
93. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3(2):231-4, 1997. PMID: 9018245.
94. Draetta GF. Cell cycle: will the real Cdk-activating kinase please stand up. Curr Biol 7(1):R50-2, 1997. PMID: 9072172.
95. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, Beach D. CDC25 phosphatases as potential human oncogenes. Science 269(5230):1575-7, 1995. PMID: 7667636.
96. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269(5224):682-5, 1995. PMID: 7624798.
97. Rolfe M, Beer-Romero P, Glass S, Eckstein J, Berdo I, Theodoras A, Pagano M, Draetta G. Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). Proc Natl Acad Sci U S A 92(8):3264-8, 1995. PMID: 7724550.
98. Basi G, Draetta G. p13suc1 of Schizosaccharomyces pombe regulates two distinct forms of the mitotic cdc2 kinase. Mol Cell Biol 15(4):2028-36, 1995. PMID: 7891698.
99. Brambilla R, Draetta G. Molecular cloning of PISSLRE, a novel putative member of the cdk family of protein serine/threonine kinases. Oncogene 9(10):3037-41, 1994. PMID: 8084611.
100. Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J 13(18):4302-10, 1994. PMID: 7523110.
101. Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M. Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression. Oncogene 9(9):2663-74, 1994. PMID: 8058330.
102. O'Connor PM, Ferris DK, Hoffmann I, Jackman J, Draetta G, Kohn KW. Role of the cdc25C phosphatase in G2 arrest induced by nitrogen mustard. Proc Natl Acad Sci U S A 91(20):9480-4, 1994. PMID: 7937793.
103. Pagano M, Theodoras AM, Tam SW, Draetta GF. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 8(14):1627-39, 1994. PMID: 7958844.
104. Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 9(3):707-18, 1994. PMID: 8108113.
105. Roussou I, Draetta G. The Schizosaccharomyces pombe casein kinase II alpha and beta subunits: evolutionary conservation and positive role of the beta subunit. Mol Cell Biol 14(1):576-86, 1994. PMID: 8264625.
106. Draetta G. Cdc2 activation: the interplay of cyclin binding and Thr161 phosphorylation. Trends Cell Biol 3(9):287-9, 1993. PMID: 14731844.
107. Marcote MJ, Knighton DR, Basi G, Sowadski JM, Brambilla P, Draetta G, Taylor SS. A three-dimensional model of the Cdc2 protein kinase: localization of cyclin- and Suc1-binding regions and phosphorylation sites. Mol Cell Biol 13(8):5122-31, 1993. PMID: 8336738.
108. Superti-Furga G, Fumagalli S, Koegl M, Courtneidge SA, Draetta G. Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. EMBO J 12(7):2625-34, 1993. PMID: 7687537.
109. Bártek J, Stasková Z, Draetta G, Lukás J. Molecular pathology of the cell cycle in human cancer cells. Stem Cells 11 Suppl 1:51-8, 1993. PMID: 8318919.
110. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7(5):812-21, 1993. PMID: 8491378.
111. Jansen-Dürr P, Meichle A, Steiner P, Pagano M, Finke K, Botz J, Wessbecher J, Draetta G, Eilers M. Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci U S A 90(8):3685-9, 1993. PMID: 8386381.
112. Pagano M, Pepperkok R, Lukas J, Baldin V, Ansorge W, Bartek J, Draetta G. Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. J Cell Biol 121(1):101-11, 1993. PMID: 8458862.
113. O'Connor PM, Ferris DK, Pagano M, Draetta G, Pines J, Hunter T, Longo DL, Kohn KW. G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem 268(11):8298-308, 1993. PMID: 8463339.
114. Clarke PR, Hoffmann I, Draetta G, Karsenti E. Dephosphorylation of cdc25-C by a type-2A protein phosphatase: specific regulation during the cell cycle in Xenopus egg extracts. Mol Biol Cell 4(4):397-411, 1993. PMID: 8389619.
115. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G. Phosphorylation and activation of human cdc25-C by cdc2--cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J 12(1):53-63, 1993. PMID: 8428594.
116. Pagano M, Dürst M, Joswig S, Draetta G, Jansen-Dürr P. Binding of the human E2F transcription factor to the retinoblastoma protein but not to cyclin A is abolished in HPV-16-immortalized cells. Oncogene 7(9):1681-6, 1992. PMID: 1323816.
117. Landesman Y, Pagano M, Draetta G, Rotter V, Fusenig NE, Kimchi A. Modifications of cell cycle controlling nuclear proteins by transforming growth factor beta in the HaCaT keratinocyte cell line. Oncogene 7(8):1661-5, 1992. PMID: 1385861.
118. Lukás J, Draetta G, Bartek J. Distinct forms of human CDC2 identified by novel monoclonal antibodies. Eur J Biochem 207(1):169-76, 1992. PMID: 1628647.
119. Marin O, Meggio F, Draetta G, Pinna LA. The consensus sequences for cdc2 kinase and for casein kinase-2 are mutually incompatible. A study with peptides derived from the beta-subunit of casein kinase-2. FEBS Lett 301(1):111-4, 1992. PMID: 1451779.
120. Buendia B, Draetta G, Karsenti E. Regulation of the microtubule nucleating activity of centrosomes in Xenopus egg extracts: role of cyclin A-associated protein kinase. J Cell Biol 116(6):1431-42, 1992. PMID: 1531830.
121. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 11(3):961-71, 1992. PMID: 1312467.
122. Pagano M, Draetta G, Jansen-Dürr P. Association of cdk2 kinase with the transcription factor E2F during S phase. Science 255(5048):1144-7, 1992. PMID: 1312258.
123. Ducommun B, Brambilla P, Draetta G. Mutations at sites involved in Suc1 binding inactivate Cdc2. Mol Cell Biol 11(12):6177-84, 1991. PMID: 1944283.
124. Ducommun B, Brambilla P, Félix MA, Franza BR, Karsenti E, Draetta G. cdc2 phosphorylation is required for its interaction with cyclin. EMBO J 10(11):3311-9, 1991. PMID: 1833185.
125. Wang HG, Draetta G, Moran E. E1A induces phosphorylation of the retinoblastoma protein independently of direct physical association between the E1A and retinoblastoma products. Mol Cell Biol 11(8):4253-65, 1991. PMID: 1830128.
126. Roth SY, Collini MP, Draetta G, Beach D, Allis CD. A cdc2-like kinase phosphorylates histone H1 in the amitotic macronucleus of Tetrahymena. EMBO J 10(8):2069-75, 1991. PMID: 2065655.
127. Howe PH, Draetta G, Leof EB. Transforming growth factor beta 1 inhibition of p34cdc2 phosphorylation and histone H1 kinase activity is associated with G1/S-phase growth arrest. Mol Cell Biol 11(3):1185-94, 1991. PMID: 1996085.
128. Brambilla P, Ducommun B, Draetta G. cdc2 protein kinase: interactions with cyclins and suc1. Cold Spring Harb Symp Quant Biol 56:515-21, 1991. PMID: 1840262.
129. Ducommun B, Draetta G, Young P, Beach D. Fission yeast cdc25 is a cell-cycle regulated protein. Biochem Biophys Res Commun 167(1):301-9, 1990. PMID: 2178610.
130. Giordano A, Whyte P, Harlow E, Franza BR, Beach D, Draetta G. A 60 kd cdc2-associated polypeptide complexes with the E1A proteins in adenovirus-infected cells. Cell 58(5):981-90, 1989. PMID: 2570639.
131. Morla AO, Draetta G, Beach D, Wang JY. Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis. Cell 58(1):193-203, 1989. PMID: 2473839.
132. Brizuela L, Draetta G, Beach D. Activation of human CDC2 protein as a histone H1 kinase is associated with complex formation with the p62 subunit. Proc Natl Acad Sci U S A 86(12):4362-6, 1989. PMID: 2543971.
133. Riabowol K, Draetta G, Brizuela L, Vandre D, Beach D. The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells. Cell 57(3):393-401, 1989. PMID: 2541912.
134. Draetta G, Luca F, Westendorf J, Brizuela L, Ruderman J, Beach D. Cdc2 protein kinase is complexed with both cyclin A and B: evidence for proteolytic inactivation of MPF. Cell 56(5):829-38, 1989. PMID: 2538242.
135. Draetta G, Piwnica-Worms H, Morrison D, Druker B, Roberts T, Beach D. Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate. Nature 336(6201):738-44, 1988. PMID: 2462672.
136. Heppel LA, Newton DL, Klee CB, Draetta GF. The phosphorylation of calmodulin and calmodulin fragments by kinase fractions from bovine brain. Biochim Biophys Acta 972(1):69-78, 1988. PMID: 2846073.
137. Draetta G, Beach D. Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement. Cell 54(1):17-26, 1988. PMID: 3289755.
138. Draetta G, Beach D, Moran E. Synthesis of p34, the mammalian homolog of the yeast cdc2+/CDC28 protein kinase, is stimulated during adenovirus-induced proliferation of primary baby rat kidney cells. Oncogene 2(6):553-7, 1988. PMID: 2838787.
139. Draetta G, Brizuela L, Beach D. p34, a protein kinase involved in cell cycle regulation in eukaryotic cells. Adv Exp Med Biol 231:453-7, 1988. PMID: 3046250.
140. Draetta G, Brizuela L, Moran B, Beach D. Regulation of the vertebrate cell cycle by the cdc2 protein kinase. Cold Spring Harb Symp Quant Biol 53 Pt 1:195-201, 1988. PMID: 3076080.
141. Draetta G, Klee CB. Purification of calmodulin-stimulated phosphodiesterase by affinity chromatography on calmodulin fragment 1-77 linked to sepharose. Methods Enzymol 159:573-81, 1988. PMID: 2842620.
142. Brizuela L, Draetta G, Beach D. p13suc1 acts in the fission yeast cell division cycle as a component of the p34cdc2 protein kinase. EMBO J 6(11):3507-14, 1987. PMID: 3322810.
143. Draetta G, Brizuela L, Potashkin J, Beach D. Identification of p34 and p13, human homologs of the cell cycle regulators of fission yeast encoded by cdc2+ and suc1+. Cell 50(2):319-25, 1987. PMID: 3297353.
144. Porta R, De Santis A, Esposito C, Draetta GF, Di Donato A, Illiano G. Inhibition of adenylate cyclase by transglutaminase-catalyzed reactions in pigeon erythrocyte ghosts. Biochem Biophys Res Commun 138(2):596-603, 1986. PMID: 2874804.
145. Putkey JA, Draetta GF, Slaughter GR, Klee CB, Cohen P, Stull JT, Means AR. Genetically engineered calmodulins differentially activate target enzymes. J Biol Chem 261(21):9896-903, 1986. PMID: 3460991.
146. Di Donato A, Draetta GF, Illiano G, Tufano MA, Sommese L, Galdiero F. Do porins inhibit the macrophage phagocyting activity by stimulating the adenylate cyclase?. J Cyclic Nucleotide Protein Phosphor Res 11(2):87-97, 1986. PMID: 2426319.
147. Illiano G, Galderisi R, Di Donato A, Paolisso G, Draetta GF. The effects of lidocaine and procainamide on the sarcolemmal membrane high affinity cyclic AMP phosphodiesterase of rat myocardium. Gen Pharmacol 16(2):115-9, 1985. PMID: 2987079.
148. Illiano G, Chiosi E, Draetta GF, Laurenza A. Relationship between the fluidity of the membrane lipids and the activity of the membrane-bound proteins: the effects of lidocaine on the adenylate cyclase activity of rat myocardium. Gen Pharmacol 14(6):669-72, 1983. PMID: 6662347.
149. Utili R, Di Donato A, Draetta G, Paolisso G, Abernathy CO, Illiano G. Endotoxin inhibits the fluoride-stimulated adenylate cyclase activity of rat liver membranes enriched with bile canaliculi. Experientia 38(7):831-3, 1982. PMID: 7049721.
150. Illiano G, Draetta GF, Laurenza A, Spina A, Paolisso G. The effects of polyamines on the cyclic AMP efflux and metabolism in E. coli B cells. Int J Biochem 13(6):701-5, 1981. PMID: 6266892.

Invited Articles

1. Carugo A, Draetta GF. Collapsing the Tumor Ecosystem: Preventing Adaptive Response to Treatment by Inhibiting Transcription. Cancer Discov 8(1):17-19, 2018. PMID: 29311224.
2. Workman P, Draetta GF, Schellens JHM, Bernards R. How Much Longer Will We Put Up With $100,000 Cancer Drugs?. Cell 168(4):579-583, 2017. PMID: 28187281.
3. Draetta GF. Commentary on "A new cancer diagnostic system based on a CDK profiling technology" [Biochim. Biophys. Acta Molecular Basis of Disease 1741 (2005) 226-233]. Biochim Biophys Acta 1741(3):225, 2005. PMID: 16183014.

Other Articles

1. Inoue A, Deem AK, Kopetz S, Heffernan TP, Draetta GF, Carugo A Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. Cancers (Basel) 11(9), 2019. PMID: 31500168.
2. Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol 18(11):e653-e706, 2017. PMID: 29208398.
3. Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 30(4):355-85, 2016. PMID: 26883357.
4. Viale A, Corti D, Draetta GF Tumors and mitochondrial respiration: a neglected connection. Cancer Res 75(18):3685-6, 2015. PMID: 26374463.
5. Viale A, Corti D, Draetta GF Tumors and Mitochondrial Respiration: A Neglected Connection. Cancer Res. PMID: 26337911.
6. Busino L, Chiesa M, Draetta GF, Donzelli M Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 23(11):2050-6, 2004. PMID: 15021892.
7. Donzelli M, Draetta GF Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep 4(7):671-7, 2003. PMID: 12835754.
8. Draetta G, Eckstein J Cdc25 protein phosphatases in cell proliferation. Biochim Biophys Acta 1332(2):M53-63, 1997. PMID: 9141461.
9. Draetta GF Mammalian G1 cyclins. Curr Opin Cell Biol 6(6):842-6, 1994. PMID: 7880531.
10. Roussou I, Draetta G Phosphorylation in yeast cell processes. Cell Signal 5(4):381-7, 1993. PMID: 8373722.
11. Marcote MJ, Pagano M, Draetta G cdc2 protein kinase: structure-function relationships. Ciba Found Symp 170:30-41; discussion 41-9, 1992. PMID: 1483349.
12. Pagano M, Draetta G Cyclin A, cell cycle control and oncogenesis. Prog Growth Factor Res 3(4):267-77, 1991. PMID: 1839823.
13. Draetta G Cell cycle control in eukaryotes: molecular mechanisms of cdc2 activation. Trends Biochem Sci 15(10):378-83, 1990. PMID: 2147521.
14. Draetta G, Beach D The mammalian cdc2 protein kinase: mechanisms of regulation during the cell cycle. J Cell Sci Suppl 12:21-7, 1989. PMID: 2699735.
15. Klee CB, Draetta GF, Hubbard MJ Calcineurin. Adv Enzymol Relat Areas Mol Biol 61:149-200, 1988. PMID: 2833077.
16. Klee CB, Ni WC, Draetta GF, Newton DL Different modes of interaction of calmodulin with its target enzymes. J Cardiovasc Pharmacol 8 Suppl 8:S52-6, 1986. PMID: 2433526.

Abstracts

1. Srinivasan S, Rose J, Minelli R, Terranova C, Shah P, Daniele JR, Peoples M, He M, Liu CY, Soeung M, Soni S, Wang F, Bristow C, Wani K, Perelli L, Loza D, Feng N, Van Loo P, Futreal A, Woodman S, Lazar A, Vellano CP, Marszalek J, Draetta GF, Heffernan T, Carugo A, Genevose G, Giuliani V. Chromosome 3 copy number loss alone drives tumor evolution to aggressive disease in uveal melanoma. Cancer Res 84(6):1758, 2024. PMID: None.
2. Rose JL, Srinivasan S, He M, Minelli R, Liu C, Terranova C, Gay J, Daniele JR, Dmitriy L, Peoples M, Soeung M, Ramamoorthy V, Shah P, Soni S, Bristow C, Wang F, Lopez A, Deckard C, Meyers B, Perelli L, Wani K, Feng N, Vellano CP, Marszalek J, Lazar AJ, Futreal A, Draetta GF, Woodman SE, Heffernan T, Genovese G, Carugo A, Giuliani V. Chromosome 3 dosage-loss informs on the unique biology underlying ultra high-risk uveal melanoma. Cancer Res 84(6):4304, 2024. PMID: None.
3. Mohamed AM, Cho KS, Soeung M, Anderson A, Alshenaifi J, Manyam G, Villareal O, Davis J, Norton W, Gao S, Bristow C, Carbone F, Napolitano S, Coker O, Khanduri I, Huang J, Maru DM, Pilato MD, Sun R, Wang L, Menter DG, Genovese G, Draetta G, Fowlkes N, Kopetz S. Anti-CSF1R antibody monotherapy inhibits minimal residual disease in a novel immunocompetent murine colorectal cancer metastasis model. Cancer Res 84(6):1168, 2024. PMID: None.
4. Soeung M, Yan X, Zhang L, Perelli L, Chen J, Tidwell BS, Khan H, Le CN, Lam TN, Bhattacharya N, Shah R, Ho I, Chen Z, Lundgren SR, Feng N, Zanca C, Karki M, Zacharias Millward NM, He R, Sheth RA, Tharakeswara BK, Rao P, Daw NC, Tripathi DN, Walker CL, Han G, Chu Y, Wang R, Dang M, Dai E, Peng F, Liu Y, Jadhav AS, Lang W, Arrechedera CA, Clemente LC, Parra-Cuentas ER, Lu H, Haymaker C, Wistuba II, Futreal A, Heffernan T, Viale A, Draetta GF, Tannir NM, Gao J, Wang L, Genovese G, Msaouel P. Hyperprogression due to myeloid mimicry in renal medullary carcinoma treated with nivolumab plus ipilimumab. Cancer Res 84(6):2702, 2024. PMID: None.
5. Srinivasan S, Rose J, Daniele JR, Peoples M, He M, Minelli R, Liu C, Gay J, Soeung M, Wani K, Perelli L, Loza D, Feng N, Vellano CP, Marszalek J, Draetta GF, Futreal P, Woodman SE, Lazar AJ, Heffernan T, Carugo A, Genovese G, Giuliani V. Deploying spatial transcriptomics to inform intratumoral heterogeneity in late-stage uveal melanoma leveraging advanced preclinical modeling and clinical samples. Cancer Res 83(7):92, 2023. PMID: None.
6. Mohamed AM, Soeung M, Alshenaifi J, Fowlkes N, Manyam G, Davis J, Anderson A, Norton W, Deem AK, Gao S, Khanduri I, Bistow C, Carbone F, Napolitano S, Huang J, Maru DM, Menter DG, Draetta GF, Genovese G, Kopetz S. Recapitulating metastatic colorectal cancer in somatic mutation models for investigating the tumor immune microenvironment in minimal residual disease. Cancer Res 83(7):77, 2023. PMID: None.
7. Bayraktar R, Tang Y, Dragomir MP, Fabris L, Draetta GF, Liang H, Calin GA. The mutational landscape of ultraconserved elements in human cancers. Cancer Res 83(7):5750, 2023. PMID: None.
8. Rose JL, Srinivasan S, He M, Minelli R, Liu C, Gay J, Daniele JR, Peoples M, Soeung M, Ramamoorthy V, Lopez A, Deckard C, Meyers B, Poggetto ED, Zamler D, Huang J, Perelli L, Wani K, Bristow C, Feng N, Vellano CP, Marszalek J, Lazar AJ, Futreal A, Draetta GF, Woodman SE, Heffernan T, Genovese G, Carugo A, Giuliani V. Advanced preclinical modeling reveals unique monosomy 3 associated biology in late-stage uveal melanoma. Cancer Res 83(7):94, 2023. PMID: None.
9. Yao W, Rose JL, Wang W, Seth S. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature 568(7752):410-414, 2019. PMID: 30918400.
10. Carugo A, Minelli R, Sapio L, Soeung M. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell, 2019. PMID: 30753823.
11. Carugo A, Draetta GF. Collapsing the Tumor Ecosystem: Preventing Adaptive Response to Treatment by Inhibiting Transcription. Cancer Discov 8 (1):17-19, 2018. PMID: 29311224.
12. Carugo A, Genovese G, Seth S, Nezi L. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as Critical Determinant of Pancreatic Cancer. Cell Rep 16 (1)(None):133-147, 2016. PMID: 27320920.
13. Ying H, Dey P, Yao W, Kimmelman AC. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 30 (4)(None):355-85, 2016. PMID: 36883357.
14. Viale A, Draetta GF. Metabolic Features of Cancer Treatment Resistance. Recent Results Cancer Research(207):135-156, 2016. PMID: 27557537.
15. Palmer WS, Poncet-Montange G, Liu G, Petrocchi, et al. Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. Journal of Medicinal Chemistry 59(4):1440-1454, 2016. PMID: None.
16. Gutschner T, Haemmerle M, Genovese G, Draetta GF, Chin L. Post-translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair. Cell Reports 14(6):1555-1556, 2016. PMID: None.
17. Chiaradonna F, Barozzi I, Miccolo C, Bucci G, et al. Redox-Mediated Suberoylanilide Hydroxamic Acide Sensitivity in Breast Cancer. Antioxidants and Redox Signaling 23(1):15-29, 2015. PMID: None.
18. Zhan Y, Kost-Alimova M, Shi X, Leo E, Bardenhagen JP, et al. Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery. Dpigenetics and Chromatin 8(1), 2015. PMID: None.
19. Viale A, Pettazzoni P, Lyssiotis CA, Ying H. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514(7534), 2014. PMID: None.
20. Kapoor A, Yao W, Ying H, Hua S, Liewen A, etal. Yap1 activation enables bypass of oncogenic KRAS addiction in pancreatic cancer. Cell 158(1), 2014. PMID: None.
21. Toniatti C, Jones P, Graham H, Pagliara B, Draetta G. Oncology drug discover: Planning a turnaround. Cancer Discovery 4(4), 2014. PMID: None.
22. Berman DM, Bosenberg MW, Orwant RL, Thurberg BL, Draetta GF, et al. Investigative pathology: Leading the post-genomic revolution. Laboratory Investigation 92(1), 2012. PMID: None.
23. Draetta GF, DePinho RA. Cancer drug discovery faces the FACT. Science Translational Medicine 3(95), 2011. PMID: None.

Book Chapters

1. Pagano M, Beer-Romero P, Glass S, Tam SW, Theodoras AM, Rolfe M, Draetta G. Targeting ubiquitin-mediated degradation for proliferation inhibitors. In: Cancer Genes. None. Plenum Publishing, 241-54, 1996.